for semaglutide, liraglutide and dulaglutide, no dose adjustment is generally required, but monitor in severe renal impairment, especially with gastrointestinal losses Pregnancy and breastfeeding: GLP-1 therapies are not recommended during pregnancy
From a patient burden standpoint, people living with advanced CKD take a number of oral medications and may prefer a once-weekly injection to an additional daily oral medication
Gradual weight loss : Working with your healthcare team to achieve steady, sustainable weight loss (rather than rapid drops) may allow skin and tissues more time to adapt
Serious but rare side effects can occur with either medication: Pancreatitis (inflammation of the pancreas) Thyroid complications Changes in vision Rapid heartbeat Severe allergic reactions Neither medication should be used if you have a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2
Shanalie Wijesinghe Content Strategy Director Shanalie Wijesinghe is the Content Strategy Director at Boulevard
While 27% of GLP-1 users say they choose foods designed for GLP-1 users, the report warns that over-medicalized positioning risks alienating non-users and replicating past health-washing failures